Compare RNTX & CMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | CMTL |
|---|---|---|
| Founded | 2001 | 1967 |
| Country | United States | United States |
| Employees | N/A | 1385 |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 52.7M |
| IPO Year | 2017 | 2024 |
| Metric | RNTX | CMTL |
|---|---|---|
| Price | $0.78 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $6.00 |
| AVG Volume (30 Days) | ★ 427.7K | 306.0K |
| Earning Date | 05-15-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.16 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $499,528,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.69 | $1.59 |
| 52 Week High | $2.18 | $6.21 |
| Indicator | RNTX | CMTL |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 46.98 |
| Support Level | $0.69 | $1.64 |
| Resistance Level | $0.88 | $1.86 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 19.75 | 81.08 |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.